[go: up one dir, main page]

HK1216755A1 - 輔助性 細胞的活化方法 - Google Patents

輔助性 細胞的活化方法

Info

Publication number
HK1216755A1
HK1216755A1 HK16104510.5A HK16104510A HK1216755A1 HK 1216755 A1 HK1216755 A1 HK 1216755A1 HK 16104510 A HK16104510 A HK 16104510A HK 1216755 A1 HK1216755 A1 HK 1216755A1
Authority
HK
Hong Kong
Prior art keywords
cell activation
activation method
auxiliary cell
auxiliary
cell
Prior art date
Application number
HK16104510.5A
Other languages
English (en)
Inventor
Hiroshi Kubo
Shinji Sogo
Haruo Sugiyama
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of HK1216755A1 publication Critical patent/HK1216755A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
HK16104510.5A 2012-12-17 2016-04-20 輔助性 細胞的活化方法 HK1216755A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012274494 2012-12-17
PCT/JP2013/083580 WO2014098012A1 (ja) 2012-12-17 2013-12-16 ヘルパーt細胞の活性化方法

Publications (1)

Publication Number Publication Date
HK1216755A1 true HK1216755A1 (zh) 2016-12-02

Family

ID=50978342

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16104510.5A HK1216755A1 (zh) 2012-12-17 2016-04-20 輔助性 細胞的活化方法

Country Status (21)

Country Link
US (1) US9833493B2 (zh)
EP (1) EP2933261B1 (zh)
JP (1) JP6530192B2 (zh)
KR (1) KR102158225B1 (zh)
CN (2) CN110195040A (zh)
AR (1) AR094026A1 (zh)
AU (1) AU2013365067B2 (zh)
BR (1) BR112015013697A2 (zh)
CA (1) CA2892660C (zh)
EA (1) EA201591168A1 (zh)
ES (1) ES2805337T3 (zh)
HK (1) HK1216755A1 (zh)
IL (1) IL239056A0 (zh)
MX (1) MX2015007745A (zh)
MY (1) MY175935A (zh)
NZ (1) NZ708990A (zh)
PH (1) PH12015501361A1 (zh)
SG (2) SG11201504530VA (zh)
TW (1) TWI646970B (zh)
UA (1) UA118962C2 (zh)
WO (1) WO2014098012A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1696027A4 (en) 2003-11-05 2008-05-14 Int Inst Cancer Immunology Inc ANTIGEN PEPTIDE BINDING TO ORIGINAL HLA-DR WT1
CA2900087C (en) 2005-10-17 2024-02-13 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
CA2645766A1 (en) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
RU2680539C2 (ru) 2007-02-27 2019-02-22 Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. Способ активации хелперных т-клеток и композиция для применения в данном способе
TW201623616A (zh) 2010-10-05 2016-07-01 癌免疫研究所股份有限公司 用於活化細胞毒性ｔ細胞的方法及組成物，及用於細胞毒性ｔ細胞之活化誘導物
CA2861206C (en) 2012-01-13 2021-07-06 Richard J. O'reilly Immunogenic wt-1 peptides and methods of use thereof
NZ708990A (en) 2012-12-17 2020-03-27 Int Inst Cancer Immunology Inc Method for activating helper t cell
AU2014207615B2 (en) 2013-01-15 2018-11-01 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
BR112017012381A2 (pt) * 2014-12-11 2018-06-19 International Institute Of Cancer Immunology, Inc. imunoterapia para doença angiogênica
CN111647066B (zh) * 2020-07-01 2020-12-18 维肽瀛(上海)生物技术有限公司 Wt1多肽肿瘤抑制剂
TW202315645A (zh) 2021-08-12 2023-04-16 日商癌免疫研究所股份有限公司 用以處置或預防癌症之醫藥組合物及方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
BRPI9912663B8 (pt) 1998-07-31 2021-07-06 Int Inst Cancer Immunology Inc vacina contra cáncer e polipeptìdeo.
PL201881B1 (pl) 1998-09-30 2009-05-29 Corixa Corp Izolowany polipeptyd składający się z immunogennej części natywnego WT1, zawierająca go kompozycja farmaceutyczna i szczepionka oraz polinukleotyd kodujący ten polipeptyd
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
NZ521430A (en) 2000-02-22 2004-04-30 Corixa Corp Compositions comprising 1-4 antigenic peptide fragments of the Wilms' tumour gene product for treatment or prevention of malignant mesothelioma
ES2298353T3 (es) 2001-03-22 2008-05-16 International Institute Of Cancer Immunology, Inc. Peptido wt1 modificado.
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
US20060165708A1 (en) 2001-06-29 2006-07-27 Chugai Seiyaku Kabushiki Kaisha Cancer vaccine containing cancer antigen based on tumor suppressor gene wt1 product and cationic liposomes
EP1447091A4 (en) 2001-09-28 2008-02-13 Institute Of Can International NEW METHOD FOR INDUCTION OF ANTIGEN SPECIFIC T CELLS
JPWO2003028758A1 (ja) 2001-09-28 2005-01-13 治夫 杉山 抗原特異的ｔ細胞の誘導方法
KR101050703B1 (ko) * 2002-06-12 2011-07-20 추가이 세이야쿠 가부시키가이샤 Ｈｌａ-ａ24-구속성 암 항원 펩티드
ES2538486T3 (es) 2002-09-12 2015-06-22 International Institute Of Cancer Immunology, Inc. Preparación de péptidos antigénicos contra el cáncer
EP1548028B1 (en) 2002-09-20 2009-09-09 International Institute of Cancer Immunology, Inc. Substituted type peptides of wt1
JP4498274B2 (ja) 2003-01-15 2010-07-07 株式会社癌免疫研究所 二量体化ペプチド
ATE538809T1 (de) 2003-06-27 2012-01-15 Int Inst Cancer Immunology Inc Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff
EP1696027A4 (en) 2003-11-05 2008-05-14 Int Inst Cancer Immunology Inc ANTIGEN PEPTIDE BINDING TO ORIGINAL HLA-DR WT1
PL1731605T3 (pl) 2004-03-31 2010-08-31 Int Inst Cancer Immunology Inc Nowotworowe peptydy antygenowe pochodzące z WT1
JP4719876B2 (ja) 2005-04-04 2011-07-06 国立大学法人愛媛大学 Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド
CA2900087C (en) 2005-10-17 2024-02-13 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
PT1961761E (pt) 2005-11-30 2010-12-16 Chugai Pharmaceutical Co Ltd Novos compostos peptídicos do tumor de wilms
US7420880B2 (en) 2005-12-29 2008-09-02 Timex Group B.V. Multimode electronic device with calibrating/setting mechanism
EP2385117B1 (en) 2006-02-22 2016-07-27 International Institute of Cancer Immunology, Inc. HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same
CA2645766A1 (en) * 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
ES2554775T3 (es) * 2006-12-28 2015-12-23 International Institute Of Cancer Immunology, Inc. Péptido WT1 restringido a HLA-A*1101 y composiciones farmacéuticas que comprenden el mismo
RU2680539C2 (ru) 2007-02-27 2019-02-22 Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. Способ активации хелперных т-клеток и композиция для применения в данном способе
KR101900639B1 (ko) 2007-03-05 2018-09-19 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
AR076349A1 (es) * 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
TW201623616A (zh) * 2010-10-05 2016-07-01 癌免疫研究所股份有限公司 用於活化細胞毒性ｔ細胞的方法及組成物，及用於細胞毒性ｔ細胞之活化誘導物
NZ708990A (en) 2012-12-17 2020-03-27 Int Inst Cancer Immunology Inc Method for activating helper t cell

Also Published As

Publication number Publication date
JPWO2014098012A1 (ja) 2017-01-12
JP6530192B2 (ja) 2019-06-12
AR094026A1 (es) 2015-07-08
EP2933261A1 (en) 2015-10-21
TW201429487A (zh) 2014-08-01
EP2933261A4 (en) 2016-07-06
WO2014098012A1 (ja) 2014-06-26
CA2892660A1 (en) 2014-06-26
CA2892660C (en) 2022-02-15
AU2013365067A1 (en) 2015-07-09
SG11201504530VA (en) 2015-07-30
NZ708990A (en) 2020-03-27
MY175935A (en) 2020-07-15
EP2933261B1 (en) 2020-06-10
CN104995203B (zh) 2019-06-28
TWI646970B (zh) 2019-01-11
SG10201705028WA (en) 2017-07-28
EA201591168A1 (ru) 2016-05-31
AU2013365067B2 (en) 2017-10-05
PH12015501361B1 (en) 2015-09-02
BR112015013697A2 (pt) 2017-11-14
PH12015501361A1 (en) 2015-09-02
CN104995203A (zh) 2015-10-21
CN110195040A (zh) 2019-09-03
US9833493B2 (en) 2017-12-05
US20150328278A1 (en) 2015-11-19
UA118962C2 (uk) 2019-04-10
KR102158225B1 (ko) 2020-09-21
ES2805337T3 (es) 2021-02-11
KR20150096697A (ko) 2015-08-25
MX2015007745A (es) 2015-12-15
IL239056A0 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
CL2014002533A1 (es) N-ciclilamidas como nematicidas
DK3363806T3 (da) Glycokonjugationsfremgangsmåde
DK2859055T3 (da) Polymercoatings
DK2864053T3 (da) Separator
DK2825087T3 (da) Otoscanner
HK1216755A1 (zh) 輔助性 細胞的活化方法
DE102012015818A8 (de) Kraftfahrzeugbatterie
DK2839013T3 (da) Ikke-disruptiv-gen-targetering
HK1190432A1 (zh) 細胞的擴增方法
DK2873977T3 (da) Dobbeltdækker-rørdispenser
DE112012006109A5 (de) Okklusionsschienenanordnung
DK2854722T3 (da) Stomipose
DE102012015817A8 (de) Kraftfahrzeugbatterie
DE112012006188B8 (de) Brennstoffzellensystem
DK2825157T3 (da) Aminosyrelipider
CL2014002030A1 (es) Alfa-amilasa
EP2911230A4 (en) CELL
DE112012006314B8 (de) Brennstoffzellensystem
DE112013002725B8 (de) Brennstoffzellensystem
HK1204655A1 (zh) 得到單核細胞或 細胞的方法
DK2831122T3 (da) Anthocyanidin-kompleks
BR112014016917A2 (pt) processamento de células
DE102012015816A8 (de) Kraftfahrzeugbatterie
DE112012006214T8 (de) Wulstringwickler
DE112012006025B8 (de) Brennstoffzellensystem